Uniphar (LON:UPR) Reaches New 12-Month High - Should You Buy?

Key Points

• Uniphar plc shares reached a new 52-week high of GBX 350 ($4.72) during trading, reflecting strong market interest.
• Brokerages maintain a mixed outlook on Uniphar with Shore Capital issuing a "buy" rating and a target price of GBX 375, while Deutsche Bank issued a "hold" rating.
• The company operates in the healthcare sector, serving over 200 pharmaceutical and medical technology manufacturers with a market capitalization of £1.07 billion.

Uniphar plc (LON:UPR - Get Free Report)'s share price hit a new 52-week high on Wednesday . The company traded as high as GBX 350 ($4.73) and last traded at GBX 349.05 ($4.71), with a volume of 11034 shares changing hands. The stock had previously closed at GBX 338.50 ($4.57).

Analyst Upgrades and Downgrades

Several analysts have issued reports on UPR shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 375 price target on shares of Uniphar in a research report on Wednesday, July 30th. Shore Capital restated a "buy" rating on shares of Uniphar in a research note on Thursday, May 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of GBX 375.

Uniphar Trading Down 0.8%

The company has a 50-day simple moving average of GBX 330.66 and a 200-day simple moving average of GBX 279.69. The company has a debt-to-equity ratio of 119.48, a quick ratio of 0.60 and a current ratio of 0.90. The stock has a market cap of £907.55 million, a P/E ratio of 1,487.79 and a beta of 0.75.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.